Opening book details…
Can I read Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab on EtoBox?
Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab by Paul M Ridker; Lynda M. Rose; John J.P. Kastelein; Raul D. Santos; Caimiao Wei; James Revkin; Carla Yunis; Jean-Claude Tardif; Charles L. Shear is a Medicine article available to read on EtoBox.
What is Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab about?
## Background: Familial hypercholesterolemia (fh) is a dominant genetic disorder associated with elevated low-density lipoprotein cholesterol (ldl-c) and premature atherosclerotic events. although therapeutic monoclonal antibodies that inhibit proprotein convertase subtilisin-kexin type 9 (pcsk9) are indicated for ldl-c reduction among adult patients with fh, placebo-controlled outcome data among fh patients are scant. ## Objective: Directly compare the efficacy of pcsk9 inhibition as compared to placebo on hard cardiovascular outcomes in fh patients enrolled in the studies of pcsk9 inhibition and the reduction of vascular events (spire) program. ## Methods: We estimated the efficacy of pcsk9 inhibition with bococizumab on future cardiovascular event rates among 1578 fh patients and 15,959 patients without fh who were selected for comparable lipid levels (on-statin levels of ldl-c >100 mg/dl or non-high-density lipoprotein cholesterol > 130 mg/dl). all patients were randomized by computer generated codes to bococizumab 150 mg subcutaneously every 2 weeks or to matching placebo in the spire clinical trials program and were followed over a median period of 11.2 months for major adver
Who reads Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab?
It is typically read by researchers, students, and practitioners in Medicine.
- Author
- Paul M Ridker; Lynda M. Rose; John J.P. Kastelein; Raul D. Santos; Caimiao Wei; James Revkin; Carla Yunis; Jean-Claude Tardif; Charles L. Shear
- Published
- 2018
- Language
- EN
- Field
- Medicine (Health Sciences)